PT1461428E - Método para produção de anticorpos híbridos - Google Patents
Método para produção de anticorpos híbridos Download PDFInfo
- Publication number
- PT1461428E PT1461428E PT02794114T PT02794114T PT1461428E PT 1461428 E PT1461428 E PT 1461428E PT 02794114 T PT02794114 T PT 02794114T PT 02794114 T PT02794114 T PT 02794114T PT 1461428 E PT1461428 E PT 1461428E
- Authority
- PT
- Portugal
- Prior art keywords
- antibody
- sequences
- hybrid antibody
- sequence
- hybrid
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 25
- 241000282414 Homo sapiens Species 0.000 claims abstract description 93
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 92
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 64
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 64
- 210000004602 germ cell Anatomy 0.000 claims abstract description 63
- 241000894007 species Species 0.000 claims description 59
- 239000012634 fragment Substances 0.000 claims description 25
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 40
- 150000001413 amino acids Chemical group 0.000 description 57
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 42
- 241001529936 Murinae Species 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 230000027455 binding Effects 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000000872 buffer Substances 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229960005091 chloramphenicol Drugs 0.000 description 12
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 12
- 241000283984 Rodentia Species 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 231100000219 mutagenic Toxicity 0.000 description 9
- 230000003505 mutagenic effect Effects 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000012670 alkaline solution Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 238000000137 annealing Methods 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
- 206010069754 Acquired gene mutation Diseases 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 230000037439 somatic mutation Effects 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000002741 site-directed mutagenesis Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 4
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 230000033607 mismatch repair Effects 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 3
- 101710094648 Coat protein Proteins 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 101710083689 Probable capsid protein Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000003471 mutagenic agent Substances 0.000 description 3
- 231100000707 mutagenic chemical Toxicity 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001056128 Homo sapiens Mannose-binding protein C Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- -1 only Chothia Chemical compound 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108060006184 phycobiliprotein Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33659101P | 2001-12-03 | 2001-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1461428E true PT1461428E (pt) | 2012-05-29 |
Family
ID=23316785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02794114T PT1461428E (pt) | 2001-12-03 | 2002-12-03 | Método para produção de anticorpos híbridos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7399594B2 (enExample) |
| EP (2) | EP1461428B1 (enExample) |
| JP (3) | JP4723810B2 (enExample) |
| AT (1) | ATE550352T1 (enExample) |
| AU (1) | AU2002359568B2 (enExample) |
| CA (1) | CA2468744C (enExample) |
| CY (1) | CY1112843T1 (enExample) |
| DK (1) | DK1461428T3 (enExample) |
| ES (1) | ES2384100T3 (enExample) |
| PT (1) | PT1461428E (enExample) |
| SI (1) | SI1461428T1 (enExample) |
| WO (1) | WO2003048321A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7393648B2 (en) * | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| CA2491669A1 (en) * | 2002-07-04 | 2004-01-15 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| KR101073590B1 (ko) * | 2003-07-15 | 2011-10-14 | 메디뮨 리미티드 | Ｉｌ-13에 대한 인간 항체 분자 |
| JP2007534307A (ja) * | 2003-11-07 | 2007-11-29 | キュラジェン コーポレイション | 分泌性白血球プロテアーゼインヒビターに対する抗体 |
| DE10353175A1 (de) * | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
| EP1531162A1 (en) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| CA2550155C (en) * | 2003-12-15 | 2015-03-17 | Dendreon Corporation | Hla-dr-specific antibodies, compositions and methods |
| EP1735615A4 (en) * | 2004-03-31 | 2009-12-02 | Centocor Ortho Biotech Inc | METHOD AND DEVICE FOR THE ANALYSIS AND GENERATION OF AMINO ACID AND NUCLEIC ACID SEQUENCES FOR HUMAN ANTIBODIES |
| WO2005111081A2 (en) * | 2004-05-10 | 2005-11-24 | Egea Biosciences, Llc | Immunoglobulin-like variable chain binding polypeptides and methods of use |
| GB0414886D0 (en) * | 2004-07-02 | 2004-08-04 | Neutec Pharma Plc | Treatment of bacterial infections |
| CA2611519A1 (en) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| FR2892724B1 (fr) * | 2005-11-02 | 2008-01-04 | Lab Francais Du Fractionnement | Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii. |
| WO2008094176A2 (en) * | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| AU2008333131B2 (en) | 2007-12-07 | 2013-10-24 | Merck Serono S/A | Humanized antibody molecules specific for IL-31 |
| EP3211010A1 (en) * | 2007-12-21 | 2017-08-30 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (il-4r) - 173 |
| CA2708074A1 (en) * | 2007-12-21 | 2009-07-02 | National Research Council Of Canada | Non-aggregating human vh domains |
| WO2009131605A2 (en) * | 2008-01-28 | 2009-10-29 | Thomas Jefferson University | Fusion partner cell line for preparation of hybrid cells expressing human antibodies |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| JP2012508022A (ja) * | 2008-11-06 | 2012-04-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 減少した免疫原性を有する操作された抗体および作製方法 |
| US8569460B2 (en) * | 2009-03-25 | 2013-10-29 | Vet Therapeutics, Inc. | Antibody constant domain regions and uses thereof |
| US9616120B2 (en) * | 2010-03-04 | 2017-04-11 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD20 |
| BR112012022342A2 (pt) * | 2010-03-04 | 2017-02-14 | Vet Therapeutics Inc | anticorpos monoclonais dirigidos a cd52 |
| AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
| CN102251013A (zh) * | 2011-02-22 | 2011-11-23 | 北京市肿瘤防治研究所 | 一个识别肿瘤起始细胞的抗体和抗原及其应用 |
| JP6392764B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ | ピロロベンゾジアゼピン−抗体結合体 |
| HRP20182129T1 (hr) * | 2012-10-12 | 2019-02-08 | Adc Therapeutics Sa | Konjugati protutijelo - pirolobenzodiazepin |
| HUE045435T2 (hu) | 2012-10-12 | 2019-12-30 | Medimmune Ltd | Pirrolobenzodiazepinek és konjugátumaik |
| RU2680267C2 (ru) | 2013-03-15 | 2019-02-19 | Мемориал Слоан Кеттеринг Кэнсер Сентер | Высокоаффинные антитела к gd2 |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| KR20200032243A (ko) | 2017-02-08 | 2020-03-25 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
| SI3612537T1 (sl) | 2017-04-18 | 2022-10-28 | Medimmune Limited | Konjugati pirolobenzodiazepina |
| EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
| KR102442736B1 (ko) | 2017-06-14 | 2022-09-16 | 에이디씨 테라퓨틱스 에스에이 | 항-cd19 adc의 투여를 위한 투약량 체제 |
| CN111065638B (zh) | 2017-08-18 | 2021-04-09 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂䓬缀合物 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| IL286326B2 (en) | 2019-03-15 | 2025-10-01 | Medimmune Ltd | Azatidobenzodiazepine dimers and conjugates containing them for use in the treatment of cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4470925A (en) * | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5643756A (en) | 1992-08-28 | 1997-07-01 | The Public Health Research Institute Of The City Of New York, Inc. | Fusion glycoproteins |
| US5723287A (en) | 1992-09-22 | 1998-03-03 | Medical Research Council | Recombinant viruses displaying a nonviral polypeptide on their external surface |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| CA2249320C (en) * | 1996-03-20 | 2008-12-23 | Immunomedics, Inc. | Glycosylated humanized b-cell specific antibodies |
| US5908925A (en) * | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
| US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US7117096B2 (en) * | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| JP2005512962A (ja) * | 2001-09-20 | 2005-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｐｄｇｆ抗体および設計抗体の産生方法 |
| US20030190705A1 (en) * | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
-
2002
- 2002-12-03 ES ES02794114T patent/ES2384100T3/es not_active Expired - Lifetime
- 2002-12-03 AT AT02794114T patent/ATE550352T1/de active
- 2002-12-03 DK DK02794114.5T patent/DK1461428T3/da active
- 2002-12-03 WO PCT/US2002/038450 patent/WO2003048321A2/en not_active Ceased
- 2002-12-03 AU AU2002359568A patent/AU2002359568B2/en not_active Ceased
- 2002-12-03 SI SI200230983T patent/SI1461428T1/sl unknown
- 2002-12-03 EP EP02794114A patent/EP1461428B1/en not_active Expired - Lifetime
- 2002-12-03 JP JP2003549500A patent/JP4723810B2/ja not_active Expired - Fee Related
- 2002-12-03 PT PT02794114T patent/PT1461428E/pt unknown
- 2002-12-03 EP EP10178484A patent/EP2298817A1/en not_active Withdrawn
- 2002-12-03 CA CA2468744A patent/CA2468744C/en not_active Expired - Fee Related
- 2002-12-03 US US10/308,817 patent/US7399594B2/en not_active Expired - Lifetime
-
2009
- 2009-04-06 JP JP2009092502A patent/JP5054058B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-13 JP JP2012056050A patent/JP2012144551A/ja not_active Withdrawn
- 2012-06-07 CY CY20121100520T patent/CY1112843T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4723810B2 (ja) | 2011-07-13 |
| SI1461428T1 (sl) | 2012-07-31 |
| JP2009153527A (ja) | 2009-07-16 |
| US20030219861A1 (en) | 2003-11-27 |
| US7399594B2 (en) | 2008-07-15 |
| CA2468744A1 (en) | 2003-06-12 |
| EP1461428B1 (en) | 2012-03-21 |
| WO2003048321A2 (en) | 2003-06-12 |
| JP2012144551A (ja) | 2012-08-02 |
| ES2384100T3 (es) | 2012-06-29 |
| WO2003048321A3 (en) | 2003-10-16 |
| ATE550352T1 (de) | 2012-04-15 |
| EP2298817A1 (en) | 2011-03-23 |
| EP1461428A4 (en) | 2005-05-25 |
| CY1112843T1 (el) | 2016-02-10 |
| JP5054058B2 (ja) | 2012-10-24 |
| CA2468744C (en) | 2013-05-14 |
| DK1461428T3 (da) | 2012-06-04 |
| JP2005511706A (ja) | 2005-04-28 |
| AU2002359568A1 (en) | 2003-06-17 |
| EP1461428A2 (en) | 2004-09-29 |
| AU2002359568B2 (en) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1461428E (pt) | Método para produção de anticorpos híbridos | |
| US8282924B2 (en) | Hybrid antibodies | |
| ES2881353T3 (es) | Intercambio de casetes de la región variable de la inmunoglobulina | |
| US20040086979A1 (en) | Humanized rabbit antibodies | |
| US20050033031A1 (en) | Methods for humanizing rabbit monoclonal antibodies | |
| US20110313134A1 (en) | Engineered antibodies with reduced immunogenicity and methods of making | |
| BRPI1007867B1 (pt) | anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente | |
| EP2281078A2 (en) | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs | |
| US9550986B2 (en) | High-throughput antibody humanization | |
| JP2011518565A5 (enExample) | ||
| HK1168114A (en) | Variant immunoglobulins with improved manufacturability |